HAYWARD, Calif., May 13 /PRNewswire-FirstCall/ -- Solta Medical,
Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics
market, today announced that it has received the Provectus Award
presented by MDB Capital Group at the first annual Bright Lights
Conference, the first public company conference to focus
exclusively on companies with disruptive and market changing
intellectual property (IP).
"We are honored to have our technological innovation recognized
by MDB Capital Group. Solta Medical has invested more than 14
years developing, validating and creating the leading IP portfolio
in the aesthetic energy device industry," said Stephen J. Fanning, Chairman of the Board,
President and Chief Executive Officer. "We will continue to
invest in the scientific research needed to develop new, innovative
aesthetic procedures." Solta Medical currently holds more
than 110 patents in the U.S. and abroad as well as over 170
additional patents pending.
The inaugural Bright Lights Conference showcased 50 of the most
innovative public companies ranked in the 90th percentile for
technology leadership from more than 1,600 small cap companies with
U.S. patents. The companies were scored, ranked and analyzed
using PatentVest, MDB's proprietary IP business intelligence
database, taking into consideration PatentVest Tech Score, 3 Year
Patent Application CAGR, number of patents granted, patent
applications on file and Application Conversion Ratio. The
companies also were judged on significance of technology within an
industry, product innovation in terms of novel or disruptive
technology, unique competitive advantages, stage of technology
development and estimated time to market.
PatentVest ranks Solta Medical in the top 5% in each of the
quantitative metrics across the entire health care sector, and
number one in IP critical mass, IP impact, IP strength and IP
growth rate.
According to PatentVest, "Among public companies in the
aesthetic equipment device (AED) industry, our IP metrics found
that Solta Medical is innovating faster and generating
game-changing IP."
"Intellectual property is no longer an intangible asset class,"
said Christopher Marlett, Chairman
and CEO of MDB Capital Group. "MDB Capital built PatentVest
to help investors easily assign a tangible value to patents, and
we've proven that market leading IP is predictive of superior
business performance. Companies like Solta Medical typify the
market leading IP presented at our Bright Lights Conference.
We are proud to recognize its achievements with the Provectus
Award, which recognizes strength of IP process leadership."
About Solta Medical, Inc.
Solta Medical, Inc. is a global leader in the medical aesthetics
market providing innovative, safe, and effective solutions for
patients that enhance and expand the practice of medical aesthetics
for physicians. The company offers products to address a range of
skin issues under the industry's three premier brands: Thermage®,
Fraxel® and Isolaz®. Thermage is an innovative, non-invasive
radiofrequency procedure for tightening and contouring skin. As the
leader in fractional laser technology, Fraxel delivers minimally
invasive clinical solutions to resurface aging and sun damaged
skin. Isolaz is the only laser or light based system indicated for
the treatment of inflammatory acne, comedonal acne, pustular acne,
and mild-to-moderate inflammatory acne. Since 2002, approximately
one million Thermage, Fraxel and Isolaz procedures have been
performed in over 100 countries. For more information about Solta
Medical, call 1-877-782-2286 or log on to www.Solta.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements are based on management's current,
preliminary expectations and are subject to risks and
uncertainties, which may cause Solta Medical's actual results to
differ materially from the statements contained herein. Further
information on potential risk factors that could affect Solta
Medical's business and its financial results are detailed in its
Form 10-K for the year ended December 31,
2009, and other reports as filed from time to time with the
Securities and Exchange Commission. Undue reliance should not be
placed on forward-looking statements which speaks only as of the
date they are made. Solta Medical undertakes no obligation to
update publicly any forward-looking statements to reflect new
information, events or circumstances after the date they were made,
or to reflect the occurrence of unanticipated events.
SOURCE Solta Medical, Inc.